Vertex Pharmaceuticals (VRTX) Projected to Release Quarterly Earnings on Monday

Key Points

• Vertex Pharmaceuticals is expected to report Q3 2026 results after the market closes on November 2. Analysts forecast earnings of $4.80 per share and revenue of $3.42 billion.
• In the prior quarter, Vertex reported $4.73 EPS—slightly below estimates—but revenue of $3.33 billion exceeded expectations and rose 12.5% year over year.
• Analyst sentiment remains positive, with a consensus “Moderate Buy” rating and an average price target of $579.81, compared with the stock’s recent price of $523.93.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) is anticipated to post its Q3 2026 results after the market closes on Monday, November 2nd. Analysts expect Vertex Pharmaceuticals to post earnings of $4.80 per share and revenue of $3.42 billion for the quarter. Parties can find conference call details on the company's upcoming Q3 2026 earnings report for the latest details on the call scheduled for Monday, November 2, 2026 at 4:30 PM ET.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last posted its earnings results on Monday, August 3rd. The pharmaceutical company reported $4.73 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.74 by ($0.01). The company had revenue of $3.33 billion for the quarter, compared to the consensus estimate of $3.23 billion. Vertex Pharmaceuticals had a net margin of 35.00% and a return on equity of 23.09%. Vertex Pharmaceuticals's revenue was up 12.5% on a year-over-year basis. During the same quarter in the prior year, the company posted $4.52 EPS. On average, analysts expect Vertex Pharmaceuticals to post $16.74 EPS for the current fiscal year and $18.44 EPS for the next fiscal year.

Vertex Pharmaceuticals Stock Performance

VRTX opened at $523.93 on Monday. The company's 50-day simple moving average is $523.52 and its two-hundred day simple moving average is $483.59. The stock has a market capitalization of $132.97 billion, a P/E ratio of 30.50, a P/E/G ratio of 2.51 and a beta of 0.28. Vertex Pharmaceuticals has a 52-week low of $403.16 and a 52-week high of $560.25.

Analyst Ratings Changes

VRTX has been the subject of a number of research analyst reports. Cantor Fitzgerald lifted their price target on shares of Vertex Pharmaceuticals from $590.00 to $595.00 and gave the stock an "overweight" rating in a research note on Tuesday, August 4th. Leerink Partners assumed coverage on shares of Vertex Pharmaceuticals in a research report on Monday, September 21st. They set an "outperform" rating and a $594.00 price objective on the stock. Rothschild & Co Redburn raised their target price on shares of Vertex Pharmaceuticals from $570.00 to $580.00 and gave the stock a "buy" rating in a report on Wednesday, August 5th. Weiss Ratings upgraded shares of Vertex Pharmaceuticals from a "buy (b-)" rating to a "buy (b)" rating in a report on Friday, October 16th. Finally, The Goldman Sachs Group set a $653.00 target price on shares of Vertex Pharmaceuticals and gave the stock a "buy" rating in a research report on Tuesday, September 1st. One research analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, Vertex Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average price target of $579.81.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated is a global biotechnology company focused on developing and commercializing medicines for serious diseases. Founded in 1989 and headquartered in Boston, Massachusetts, the company applies expertise in the science of human disease to discover therapies that address significant unmet medical needs.

Vertex is best known for its cystic fibrosis portfolio, which includes Kalydeco, Orkambi, Symdeko/Symkevi, and Trikafta/Kaftrio. These medicines target the underlying cause of cystic fibrosis for patients with specific mutations in the CFTR gene.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.